Taken together, our findings reveal that AR-induced LINC01503 can promote NPC progression through the SFPQ-FOSL1 axis, which represents a novel prognostic biomarker and therapeutic target for NPC patients. The gene discussed is FOSL1; the disease is nasopharyngeal carcinoma.